CLINICAL TRIALS PROFILE FOR RECLAST
✉ Email this page to a colleague
All Clinical Trials for RECLAST
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00171964 ↗ | Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions | Completed | Novartis Pharmaceuticals | Phase 4 | 2002-05-01 | It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and analgesic consumption. |
| NCT00305695 ↗ | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-11-28 | This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery to remove the ovaries. |
| NCT00305695 ↗ | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | Completed | Gynecologic Oncology Group | Phase 2 | 2005-11-28 | This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery to remove the ovaries. |
| NCT00439647 ↗ | Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis | Completed | Novartis Pharmaceuticals | Phase 3 | 2006-12-01 | This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis. |
| NCT00556374 ↗ | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | Active, not recruiting | Austrian Breast and Colorectal Cancer Study Group | Phase 3 | 2006-12-18 | The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy. |
| NCT00556374 ↗ | Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | Active, not recruiting | Amgen | Phase 3 | 2006-12-18 | The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RECLAST
Condition Name
Clinical Trial Locations for RECLAST
Trials by Country
Clinical Trial Progress for RECLAST
Clinical Trial Phase
Clinical Trial Sponsors for RECLAST
Sponsor Name
